Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Stephens Inc. AR

Stephens Inc. AR lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 61.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,607 shares of the medical research company's stock after selling 2,603 shares during the period. Stephens Inc. AR's holdings in Charles River Laboratories International were worth $242,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. D1 Capital Partners L.P. acquired a new position in shares of Charles River Laboratories International in the fourth quarter worth about $172,752,000. Assenagon Asset Management S.A. increased its stake in shares of Charles River Laboratories International by 1,721.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company's stock worth $85,811,000 after purchasing an additional 538,792 shares during the last quarter. Norges Bank acquired a new stake in shares of Charles River Laboratories International in the fourth quarter worth $98,886,000. Wellington Management Group LLP lifted its stake in shares of Charles River Laboratories International by 9.0% in the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after buying an additional 335,658 shares during the last quarter. Finally, Nomura Holdings Inc. acquired a new stake in shares of Charles River Laboratories International in the fourth quarter worth $56,820,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president owned 19,513 shares of the company's stock, valued at approximately $2,837,385.33. This represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on CRL. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and lowered their price target for the company from $188.00 to $182.00 in a report on Friday, May 23rd. Citigroup raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and boosted their price target for the company from $150.00 to $200.00 in a report on Wednesday, July 9th. Robert W. Baird boosted their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a report on Thursday, May 8th. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target on the stock in a report on Wednesday, May 14th. Finally, Mizuho lowered their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $174.54.

Charles River Laboratories International Price Performance

Shares of CRL opened at $154.55 on Monday. The stock has a market capitalization of $7.59 billion, a P/E ratio of -237.77, a P/E/G ratio of 5.23 and a beta of 1.49. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The company has a 50 day moving average of $147.42 and a 200-day moving average of $150.35. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.78.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The business's quarterly revenue was down 2.7% on a year-over-year basis. During the same period last year, the business earned $2.27 EPS. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.